Evidence map›Paper›PMID 39105759›Full record

ReviewInnere Medizin (Heidelberg, Germany)2024

[What is confirmed in the treatment of Fabry's disease?]

Malte Lenders, Eva Brand

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Innere Medizin (Heidelberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Malte LendersAllgemeine Innere Medizin D sowie Nieren- und Hochdruckkrankheiten und Rheumatologie, Interdisziplinäres Fabry Zentrum (IFAZ), Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Deutschland.
Eva BrandAllgemeine Innere Medizin D sowie Nieren- und Hochdruckkrankheiten und Rheumatologie, Interdisziplinäres Fabry Zentrum (IFAZ), Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Deutschland. Eva.Brand@ukmuenster.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fabry's disease is a rare X chromosome-linked inherited lysosomal storage disease characterized by insufficient metabolism of the substrate globotriaosylceramide (Gb

Indexed as

alpha-GalactosidaseEnzyme Replacement TherapyFabry Disease1-DeoxynojirimycinFemaleHumansIsoenzymesMaleRecombinant Proteins1-Deoxynojirimycinagalsidase alfaagalsidase betaalpha-GalactosidaseIsoenzymesmigalastatRecombinant ProteinsEnzyme replacement therapyGene therapyLysosomal storage diseasesMolecular chaperonesSubstrate reduction therapy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.